**To the Editor:** Global emergence of reassortant rotavirus A (RVA) strains possessing the DS-1 backbone genes, such as DS-1--like G1P\[8\] strains ([@R1]--[@R3]), raises 2 key questions of public health importance. First, is the G1P\[8\] monovalent vaccine (RV1) effective against the DS-1--like G1P\[8\] strain? Second, does this strain cause more severe disease than the Wa-like G1P\[8\] strain?

For the first question, Jere et al. ([@R1]) showed that RV1 was highly effective against DS-1--like G1P\[8\] RVAs (vaccine effectiveness \[VE\] 85.6% \[95% CI 34.4%--96.8%\]). For the second question, we conducted a study in Hanoi, Vietnam, during the 2012--2013 rotavirus season in which 20 DS-1--like G1P\[8\] RVAs co-circulated with 49 Wa-like G1P\[8\] RVAs and 50 G2P\[4\] RVAs among children \<2 years of age who had diarrhea. We found no evidence of increased virulence of DS-1--like G1P\[8\] strains as measured by Vesikari's severity scores ([@R3]).

However, Jere et al. ([@R1]) were unable to demonstrate statistically significant VE against DS-1--like G2P\[4\] or Wa-like G1P\[8\] strains and were concerned about the low point estimate of the VE against heterotypic G2P\[4\] strains. Using the previous dataset ([@R3]), we conducted a post hoc logistic regression analysis to compare any RV1 vaccination status versus 0-dose RV1 vaccination status between strain-specific rotavirus diarrhea case-patients and 127 acute respiratory infection control patients whose RV1 coverage was 49.6%. We calculated VE against DS-1--like G1P\[8\] as 72.5% (95% CI 10.8%--91.5%; p = 0.045), VE against Wa-like G1P\[8\] as 90.8% (95% CI 72.9%--96.9%), and VE against G2P\[4\] as 78.1% (95% CI 49.1%--90.6%). These findings confirm the effectiveness of RV1 against fully heterotypic G2P\[4\] strains, as shown elsewhere ([@R4],[@R5]), and supplement the study by Jere et al. ([@R1]) in helping dismiss concern about continued use of the monovalent vaccine, even in places where RVAs with the DS-1 backbone are not uncommon.
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